Novel taste-masked orally disintegrating tablets for a highly soluble drug with an extremely bitter taste: Design rationale and evaluation

Drug Development and Industrial Pharmacy

Volumn 39, Issue 9, 2013, Pages 1364-1371

  Tan, Qunyou ^a   Zhang, Li ^b   Liu, Guodong ^a   He, Dan ^b   Yin, Huafeng ^b   Wang, Hong ^b   Wu, Jianyong ^b   Liao, Hong ^b   Zhang, Jingqing ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Bioequivalence; Central composite design; Orally disintegrating tablets; Pyridostigmine bromide; Solid dispersions; Taste masked

Indexed keywords

CROSPOVIDONE; EUDRAGIT; MICROCRYSTALLINE CELLULOSE; PYRIDOSTIGMINE;

ARTICLE; BIOEQUIVALENCE; BITTER TASTE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; EVAPORATION; FEMALE; HUMAN; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; NORMAL HUMAN; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PROCESS OPTIMIZATION; STOMACH JUICE; TABLET; TABLET DISINTEGRATION;

ANIMALS; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; EXCIPIENTS; FEMALE; FLAVORING AGENTS; HUMANS; KINETICS; MALE; MODELS, CHEMICAL; PHYSICOCHEMICAL PHENOMENA; POLYMETHACRYLIC ACIDS; POVIDONE; PYRIDOSTIGMINE BROMIDE; RABBITS; RANDOM ALLOCATION; SALIVA; SOLUBILITY; TABLETS; TASTE; THERAPEUTIC EQUIVALENCY;

EID: 84881139713     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.718784     Document Type: Article

References (37)

1. Abdelbary G, Prinderre P, Eouani C, Joachim J, Reynier JP, Piccerelle P. (2004). The preparation of orally disintegrating tablets using a hydrophilic waxy binder. Int J Pharm, 278:423-433. (Pubitemid 38759514)
2. Shah PP, Mashru RC. (2008). Development and evaluation of artemether taste masked rapid disintegrating tablets with improved dissolution using solid dispersion technique. AAPS PharmSciTech, 9:494-500.
3. Dobetti L. (2001). Fast-melting tablets: developments and technologies. Pharm Technol, 44-50.
4. Masaki K. (1997). Orally disintegrating famotidine tablets, 22nd Conference on Pharmaceutical Technology. pp 15-17.
5. Mizumoto T, Tamura T, Kawai H, Kajiyama A, Itai S. (2008). Formulation design of taste-masked particles, including famotidine, for an oral fastdisintegrating dosage form. Chem Pharm Bull, 56:530-535. (Pubitemid 351520139)
6. Sammour OA, Hammad MA, Megrab NA, Zidan AS. (2006). Formulation and optimization of mouth dissolve tablets containing rofecoxib solid dispersion. AAPS PharmSciTech, 7:1-9.
7. Katou S, Kearney P, Yarwood RJ. (1993). The zydis fast dissolving oral dosage form. Pharm Tech Jpn 9:713-719.
8. Wehling F, Schuehle S, Madamala N. Effervescent dosage form and method of administering same. 1991, WO91/04757.
9. Cousin G, Bruna E, Madamala N. Rapidly disintegratable multiparticular tablet. 1995, US Patent 5464632.
10. Kluwe WM, Page JG, Toft JD, Ridder WE, Chung H. (1990). Pharmacological and toxicological evaluation of orally administered pyridostigmine in dogs. Fundam Appl Toxicol, 14:40-53. (Pubitemid 20097353)
11. Tan QY, Hu NN, Liu GD, Yin HF, Zhang L, Wang H et al. (2012). Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. Arch Pharm Res, 35:499-508.
12. Tan QY, Xu ML, Wu JY, Yin HF, Zhang JQ. (2012). Preparation and characterization of poly(lactic acid) nanoparticles for sustained release of pyridostigmine bromide. Pharmazie, 67:311-318.
13. Randale SA, Dabhi CS, Tekade AR, Belgamwar VS, Gattani SG, Surana SJ. (2010). Rapidly disintegrating tablets containing taste masked metoclopramide hydrochloride prepared by extrusionprecipitation method. Chem Pharm Bull, 58:443-448.
14. Xu J, Bovet LL, Zhao K. (2008). Taste masking microspheres for orally disintegrating tablets. Int J Pharm, 359:63-69.
15. Yan YD, Woo JS, Kang JH, Yong CS, Choi HG. (2010). Preparation and evaluation of taste-masked donepezil hydrochloride orally disintegrating tablets. Biol Pharm Bull, 33:1364-1370.
16. Jijun F, Lishuang X, Xiaoli W, Shu Z, Xiaoguang T, Xingna Z et al. (2011). Nimodipine (NM) tablets with high dissolution containing NM solid dispersions prepared by hot-melt extrusion. Drug Dev Ind Pharm, 37:934-944.
17. Funasaki N, Uratsuji I, Okuno T, Hirota S, Neya S. (2006). Masking mechanisms of bitter taste of drugs studied with ion selective electrodes. Chem Pharm Bull, 54:1155-1161. (Pubitemid 44166408)
18. Kayumba PC, Huyghebaert N, Cordella C, Ntawukuliryayo JD, Vervaet C, Remon JP. (2007). Quinine sulphate pellets for flexible pediatric drug dosing: formulation development and evaluation of taste-masking efficiency using the electronic tongue. Eur J Pharm Biopharm, 66:460-465. (Pubitemid 46756222)
19. Laitinen R, Suihko E, Bjorkqvist M, Riikonen J, Lehto VP, Jarvinen K et al. (2010). Perphenazine solid dispersions for orally fastdisintegrating tablets: physical stability and formulation. Drug Dev Ind Pharm, 36:601-613.
20. Rahman Z, Zidan AS, Khan MA. (2010). Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation. Int J Pharm, 400:49-58.
21. Otsuka T, Iwao Y, Miyagishima A, Itai S. (2011). Application of principal component analysis enables to effectively find important physical variables for optimization of fluid bed granulator conditions. Int J Pharm, 409:81-88.
22. Law SL, Chiang CH. (1990). Improving dissolution rates of griseofulvin by deposition on disintegrants. Drug Develop Ind Pharm, 16:137-147. (Pubitemid 20027627)
23. Gao Y, Cui FD, Guan Y, Yang L, Wang YS, Zhang LN. (2006). Preparation of roxithromycin-polymeric microspheres by the emulsion solvent diffusion method for taste masking. Int J Pharm, 318:62-69. (Pubitemid 43983049)
24. Zhang JQ, Liu J, Li XL, Jasti BR. (2007). Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv, 14:381-387. (Pubitemid 47265822)
25. Tan QY, Wang N, Yang H, Chen L, Xiong HR, Zhang LK et al. (2010). Preparation and characterization of lipid vesicles containing uricase. Drug Deliv, 17:28-37.
26. Ye G, Wang S, Heng PW, Chen L, Wang C. (2007). Development and optimization of solid dispersion containing pellets of itraconazole prepared by high shear pelletization. Int J Pharm, 337:80-87. (Pubitemid 46756037)
27. Bourne DWA. (2009). Chapter 3, Pharmacokinetics in Modern Pharmaceutics. In: Florence AT, Siepmann J. eds., Volume 1 Basic Principles and Systems, 5th ed. New York, NY:Informa Healthcare. 81-116.
28. Ermer JC, Dennis K, Haffey MB, Doll WJ, Sandefer EP, Buckwalter M et al. (2011). Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, twoperiod, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. Clin Drug Investig, 31:357-370.
29. Liu YM, Liu GY, Liu Y, Li SJ, Jia JY, Zhang MQ et al. (2009). Pharmacokinetic and bioequivalence comparison between orally disintegrating and conventional tablet formulations of flurbiprofen: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male volunteers. Clin Ther, 31:1787-1795.
30. Tan QY, Wang N, Yang H, Zhang LK, Liu S, Chen L et al. (2010). Characterization, stabilization and activity of uricase loaded in lipid vesicles. Int J Pharm, 384:165-172.
31. Husain MA, Roberts JB, Thomas BH, Wilson A. (1968). The excretion and metabolism of oral 14C-pyridostigmine in the rat. Br J Pharmacol, 34:445-450.
32. Zhang JQ, Zhang ZR, Yang H, Tan QY, Qin SR, Qiu XL. (2005). Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. Pharm Res, 22:573-583. (Pubitemid 40603255)
33. Tan QY, Zhang JQ, Wang N, Yang H, Li X, Xiong HR, Wu JY, Zhao CJ, Wang H, Yin HF. (2012). Improved biological properties and hypouricaemic effects of uricase from Candida utilis loaded in novel alkaline enzymosomes. Int J Nanomedicine, 7:3929-3938
34. Lu B, Zhang JQ, Yang H. (2003). Nonphospholipid vesicles of Carboplatin for lung targeting. Drug Deliv, 10:87-94. (Pubitemid 36588509)
35. Huang YT, Tsai TR, Cheng CJ, Cham TM, Lai TF, Chuo WH. (2007). Formulation design of a highly hygroscopic drug (pyridostigmine bromide) for its hygroscopic character improvement and investigation of in vitro/in vivo dissolution properties. Drug Dev Ind Pharm, 33:403-416.
36. Shukla D, Chakraborty S, Singh S, Mishra B. (2009). Fabrication and evaluation of taste masked resinate of risperidone and its orally disintegrating tablets. Chem Pharm Bull, 57:337-345.
37. Pedersen AM, Bardow A, Jensen SB, Nauntofte B. (2002). Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis, 8:117-129. (Pubitemid 34535060)